Grant supports company's R&D of therapies for type 1 diabetes.
SAN DIEGO, Calif., February 23, 2017 -- Beyond Type 1, a not-for-profit advocacy and education group for Type 1 diabetics, has awarded a grant to ViaCyte, Inc., a privately-held regenerative medicine company, to support development of a cure for Type 1 and other insulin-requiring diabetes.
For more than a decade, ViaCyte has been developing innovative stem cell-derived cell replacement therapies with a focus on the treatment of insulin-requiring diabetes.
The company's pluripotent stem cell-derived islet cell replacement therapy, the PEC-Direct product candidate, has the potential to be a breakthrough treatment for high-risk Type 1 diabetes.
The PEC-Direct product candidate is expected to begin clinical trials this year and is likely to be the company's first approved product.
ViaCyte's PEC-Encap (also known as VC-01) product candidate delivers the same cell therapy as the PEC-Direct product candidate but in a delivery device designed to protect the cells from the patient's immune system, and therefore will not require immunosuppressant drugs commonly used for organ and tissue transplants.
The PEC-Encap product candidate is being developed to treat all patients with diabetes who use insulin to control their disease.
Preliminary clinical results with the PEC-Encap product candidate have provided early indications of the potential of the approach.
"Beyond Type 1 views ViaCyte's products as potentially game-changing for those suffering with Type 1 diabetes, and seeks to promote their continued safe and efficient development," said CEO Sarah Lucas. "ViaCyte's mission to create a functional cure for Type 1 diabetes is well-aligned with Beyond Type 1's goals."
All funds donated to Beyond Type 1 can be used to directly support the portfolio of partner organizations.
Beyond Type 1 creates and funds a portfolio of programs, technologies, and innovations that those living with Type 1 diabetes need to manage, live, and thrive.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Grants & Contracts|
|Publication:||Stem Cell Business News|
|Date:||Mar 6, 2017|
|Previous Article:||$12.2M grant from CIRM supports phase 2 trial of diabetes treatment.|
|Next Article:||U.S. patent covers neuralstem's small molecule compound.|